Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland
The results of this cohort study suggest that, in contrast to Germany and Switzerland, prices of cancer drugs increased substantially post launch in the US. When developing solutions how drug prices can be decreased, launch as well as postlaunch prices require attention from policymakers.
Authors
- Yannic Laube
- Kerstin Noëlle Vokinger (ORCID: https://orcid.org/0000-0002-6997-7384)
- Miquel Serra‐Burriel (ORCID: https://orcid.org/0000-0001-8595-1224)
- C. Glaus
Institutions
- University of Zurich (CH)
- ETH Zurich (CH)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1001/jamahealthforum.2024.4461
- Citations
- 8
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 10.16
Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung